Research Highlights

Joint press release by the Max Delbrück Center and the Helmholtz Centre for Infection Research One...

In aggressive lymphomas, inflammatory messengers reprogram the “conductors” of the immune system, causing lymph node structure to collapse. A team led by Simon Haas describes in “Nature Cancer” this process for the first time using single-cell and spatial analyses.

Researchers at the Max Delbrück Center and Charité – Universitätsmedizin Berlin show that adipose tissue amplifies gut inflammation in Crohn’s disease. The study, published in the “Journal of Clinical Investigation,” also reveals how genetic changes in immune cells may contribute to the disease.

Researchers have uncovered the molecular details of how ancient viral DNA controls a gene linked to preeclampsia. The study, published in “Genome Biology,” builds on previous research and may lead to a diagnostic test to identify preeclampsia risk much earlier.

Researchers at the Max Delbrück Center have uncovered how a bacterial metabolite produced in the gut regulates heart function through specific brain cells. The findings, published in “Circulation Research,” reveal a new gut-brain-heart axis and point to potential therapies for hypertension and heart failure.

Researchers at the Max Delbrück Center show that two closely related enzymes, MNK1 and MNK2, act on the brain to regulate different behaviors. Their findings, published in “Molecular Psychiatry,” could help guide development of more precise therapies for neurological disorders.

MRI scans often struggle to capture clear images of deep or delicate tissues. Researchers at the Max Delbrück Center now report in “Advanced Materials” a new lightweight antenna that boosts image quality and may shorten scan times ¬– without changing existing MRI machines.

Researchers at the Max Delbrück Center have developed a fast, cost-effective blood-based tool that can identify and classify immune deficiencies with high accuracy. The approach, published in “Nature Communications,” could help address long-standing gaps in diagnosing immune disorders.

Different drugs that bind to the same receptor in the cell membrane were long thought to activate cells in the same way. A study in “Nature,” however, suggests this understanding is too simplistic and highlights a way to develop drugs that are more precise and cause fewer side effects.

Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In “Molecular Therapy,” a team led by Armin Rehm presents an improved immunotherapy that recognizes two distinct features of malignant cells to destroy the cancer more effectively.